Project: An MRI-based technology for early assessment of antidepressant efficacy in depression.
| Acronym | DEPREDICT (Reference Number: 113351) |
| Duration | 01/10/2019 - 03/10/2022 |
| Project Topic | The consortium will develop DEPREDICT: a software tool that allows early assessment of response to an antidepressant within 2 weeks after first administration, in patients with major depressive disorder (MDD). The software tool will be developed using artificial intelligence to identify predictive MRI signatures from clinical data and advanced MRI analysis technology. The signatures will be integrated into an assessment tool fully integrated in a cloud-based MRI analysis software environment. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | NordicNeuroLab AS | Coordinator | Norway |
| 2 | Academic Medical Center Amsterdam, part of Amsterdam UMC | Partner | Netherlands |
| 3 | Oslo Universitetssykehus | Partner | Norway |
| 4 | Vuno, Inc. | Partner | Korea, Republic of |